This interest in experimental drugs and vaccines drew investors to any biotech stock that was remotely doing anything avian-related in nature. Sadly, like Tulipomania, dot-coms, and nanotechnology stocks, investors who rolled the dice on bird flu stocks—for the most part—have lost, ending up with a come-out roll of 2, 3 or 12 on their pass-line bet.
15 plays on bird flu
Symmetrel, FDA-approved to treat influenza A *
Rec'd $6M grant from U.S. to develop H5N1 vaccine
Imunostimulatory sequence technology to target virus
Developing DNA-based vaccine vs. H5N1
Announced plans to research H5N1 vaccine
PER.C6 tech used by Sanofi in H5N1 vaccine development
Alferon, stimulates Interferon to defend vs. H5N1
Technology may help speed H5N1 vaccine development
Peramivir, which may inhibit H5N1 virus
Announced plan to develop RNAi therapeutic for H5N1
Developoing anti-H5N1 vaccine w/ Antigen Express tech
Microarray for typing flu viruses
DNA test for flu viruses
Anflu, licensed in China as antiflu vaccine
Source: PharmaWeek; MSN Money; company reports;
Prudent investors would have been wise to heed an NASD alert issued back in December 2005, Bird Flu Stock Scam Could Be Hazardous To Your Financial Health, that warned of companies claiming to be poised to capitalize on helping the world avoid a global pandemic with allegedly proprietary breakthrough treatments.
Editor David J Phillips holds no financial interest in any of the stocks mentioned in this article. The 10Q Detective has a FULL DISCLOSURE policy.